Geneos Therapeutics, Inc. - Preferred stock Investment (Details) - USD ($) |
1 Months Ended | 3 Months Ended | |
|---|---|---|---|
Mar. 31, 2022 |
Mar. 31, 2023 |
Mar. 31, 2022 |
|
| Noncontrolling Interest [Line Items] | |||
| Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022 | $ 0 | $ (2,165,213) | |
| Series A-2 One Preferred Stock | |||
| Noncontrolling Interest [Line Items] | |||
| Beginning balance | $ 1,999,998 | ||
| Remeasurement of Geneos Series A-1 preferred stock | $ 165,215 | ||
| Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022 | (2,165,213) | ||
| Ending balance | $ 0 | $ 0 | |
| X | ||||||||||
- Definition Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|